More Australians with blood cancer reliant on blood donations than ever before
- Media releases
- Research
Two new international clinical trials are expected to improve access to new therapies for Australians with MDS as part of the Leukaemia Foundation’s Trials Enabling Program (TEP).
Julian Lindsay’s goal is to set up an international study aimed at improving survival and quality of life through drug optimisation.
An Australian study will examine the immune response to the COVID-19 vaccine in patients with the low-grade non-Hodgkin lymphomas.
Associate Professor Michael Dickinson says CAR T-cell therapy is a 'revolutionary step forward'.
Not only is Professor Miles Prince “a true believer in CAR T-cells”, he believes they may even have the potential to cure myeloma one day.
Dr Melissa Cantley hopes that those who have this pre-canerous condition will be able to be tested to understand their risk of developing myeloma.
Dr Rishi Kotecha talks about the revolutionary treatments which are improving outcomes for babies and children with high-risk leukaemia.